{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:08:20Z","timestamp":1770746900527,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,29]]},"DOI":"10.7759\/cureus.44340","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T19:11:28Z","timestamp":1693336288000},"source":"Crossref","is-referenced-by-count":1,"title":["Prevalence and Visual Consequences of Non-adherent Patients Receiving Anti-vascular Endothelial Growth Factor (VEGF) Injections at King Fahad Specialist Hospital (KFSH), Qassim Region"],"prefix":"10.7759","author":[{"given":"Abdulmajeed  D","family":"Alharbi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noura I","family":"Alotayk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulmajeed A","family":"Alaboudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrahman  y","family":"Alammar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad I","family":"Aldekhail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meshari A","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thekra A","family":"Alsamel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhannad  A","family":"Aljutayli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman M","family":"Aljarbou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama M","family":"Aljameeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.15537\/smj.2018.10.22938","article-title":"Knowledge and awareness of diabetes mellitus and its risk factors in Saudi Arabia","volume":"39","author":"Alanazi FK","year":"2018","unstructured":"Alanazi FK, Alotaibi JS, Paliadelis P, Alqarawi N, Alsharari A, Albagawi B. Knowledge and awareness of diabetes mellitus and its risk factors in Saudi Arabia. Saudi Med J. 2018, 39:981-9. 10.15537\/smj.2018.10.22938","journal-title":"Saudi Med J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.1.226","article-title":"Diabetic retinopathy","volume":"26","author":"Fong DS","year":"2003","unstructured":"Fong DS, Aiello L, Gardner TW, et al.. Diabetic retinopathy. Diabetes Care. 2003, 26:226-9. 10.2337\/diacare.26.1.226","journal-title":"Diabetes Care"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17091498","article-title":"Moving past anti-VEGF: novel therapies for treating diabetic retinopathy","volume":"17","author":"Bolinger MT","year":"2016","unstructured":"Bolinger MT, Antonetti DA. Moving past anti-VEGF: novel therapies for treating diabetic retinopathy. Int J Mol Sci. 2016, 17:1498. 10.3390\/ijms17091498","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005139.pub4","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"3","author":"Solomon SD","year":"2019","unstructured":"Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2019, 3:CD005139. 10.1002\/14651858.CD005139.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14946","article-title":"The impact of compliance among patients with diabetic macular oedema treated with intravitreal aflibercept: a 48-month follow-up study","volume":"100","author":"Angermann R","year":"2022","unstructured":"Angermann R, Hofer M, Huber AL, et al.. The impact of compliance among patients with diabetic macular oedema treated with intravitreal aflibercept: a 48-month follow-up study. Acta Ophthalmol. 2022, 100:e546-52. 10.1111\/aos.14946","journal-title":"Acta Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S325763","article-title":"Importance of treatment duration: unmasking barriers and discovering the reasons for undertreatment of anti-VEGF agents in neovascular age-related macular degeneration","volume":"15","author":"Sobolewska B","year":"2021","unstructured":"Sobolewska B, Sabsabi M, Ziemssen F. Importance of treatment duration: unmasking barriers and discovering the reasons for undertreatment of anti-VEGF agents in neovascular age-related macular degeneration. Clin Ophthalmol. 2021, 15:4317-26. 10.2147\/OPTH.S325763","journal-title":"Clin Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0233595","article-title":"Effectiveness and safety of ranibizumab 0.5 mg in treatment-na\u00efve patients with diabetic macular edema: results from the real-world global LUMINOUS study","volume":"15","author":"Mitchell P","year":"2020","unstructured":"Mitchell P, Sheidow TG, Farah ME, et al.. Effectiveness and safety of ranibizumab 0.5 mg in treatment-na\u00efve patients with diabetic macular edema: results from the real-world global LUMINOUS study. PLoS One. 2020, 15:e0233595. 10.1371\/journal.pone.0233595","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-023-02261-x","article-title":"Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis","volume":"12","author":"Shahzad H","year":"2023","unstructured":"Shahzad H, Mahmood S, McGee S, et al.. Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis. Syst Rev. 2023, 12:92. 10.1186\/s13643-023-02261-x","journal-title":"Syst Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld PJ","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006, 355:1419-31. 10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study","volume":"116","author":"Brown DM","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009, 116:57-65.e5. 10.1016\/j.ophtha.2008.10.018","journal-title":"Ophthalmology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.09.004","article-title":"Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study","volume":"118","author":"Schmidt-Erfurth U","year":"2011","unstructured":"Schmidt-Erfurth U, Eldem B, Guymer R, et al.. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011, 118:831-9. 10.1016\/j.ophtha.2010.09.004","journal-title":"Ophthalmology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.04.011","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2","volume":"150","author":"Abraham P","year":"2010","unstructured":"Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol. 2010, 150:315-324.e1. 10.1016\/j.ajo.2010.04.011","journal-title":"Am J Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.04.001","article-title":"Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting","volume":"148","author":"Cohen SY","year":"2009","unstructured":"Cohen SY, Dubois L, Tadayoni R, et al.. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol. 2009, 148:409-13. 10.1016\/j.ajo.2009.04.001","journal-title":"Am J Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318240a516","article-title":"Causes of unsuccessful ranibizumab treatment in exudative age-related macular degeneration in clinical settings","volume":"32","author":"Cohen SY","year":"2012","unstructured":"Cohen SY, Oubraham H, Uzzan J, Dubois L, Tadayoni R. Causes of unsuccessful ranibizumab treatment in exudative age-related macular degeneration in clinical settings. Retina. 2012, 32:1480-5. 10.1097\/IAE.0b013e318240a516","journal-title":"Retina"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"Chakravarthy U","year":"2012","unstructured":"Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012, 119:1399-411. 10.1016\/j.ophtha.2012.04.015","journal-title":"Ophthalmology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.3578","article-title":"Loss to follow-up among patients with neovascular age-related macular degeneration who received intravitreal anti-vascular endothelial growth factor injections","volume":"136","author":"Obeid A","year":"2018","unstructured":"Obeid A, Gao X, Ali FS, et al.. Loss to follow-up among patients with neovascular age-related macular degeneration who received intravitreal anti-vascular endothelial growth factor injections. JAMA Ophthalmol. 2018, 136:1251-9. 10.1001\/jamaophthalmol.2018.3578","journal-title":"JAMA Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.02.034","article-title":"Loss to follow-up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal anti-VEGF injections","volume":"125","author":"Obeid A","year":"2018","unstructured":"Obeid A, Gao X, Ali FS, et al.. Loss to follow-up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal anti-VEGF injections. Ophthalmology. 2018, 125:1386-92. 10.1016\/j.ophtha.2018.02.034","journal-title":"Ophthalmology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2018.11.002","article-title":"Loss to follow-up after intravitreal anti-vascular endothelial growth factor injections in patients with diabetic macular edema","volume":"3","author":"Gao X","year":"2019","unstructured":"Gao X, Obeid A, Aderman CM, et al.. Loss to follow-up after intravitreal anti-vascular endothelial growth factor injections in patients with diabetic macular edema. Ophthalmol Retina. 2019, 3:230-6. 10.1016\/j.oret.2018.11.002","journal-title":"Ophthalmol Retina"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.03.023","article-title":"Predictors of lost to follow-up in patients being treated for proliferative diabetic retinopathy","volume":"216","author":"Green M","year":"2020","unstructured":"Green M, Tien T, Ness S. Predictors of lost to follow-up in patients being treated for proliferative diabetic retinopathy. Am J Ophthalmol. 2020, 216:18-27. 10.1016\/j.ajo.2020.03.023","journal-title":"Am J Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.03.011","article-title":"Loss to follow-up among patients with proliferative diabetic retinopathy in clinical practice","volume":"215","author":"Suresh R","year":"2020","unstructured":"Suresh R, Yu HJ, Thoveson A, et al.. Loss to follow-up among patients with proliferative diabetic retinopathy in clinical practice. Am J Ophthalmol. 2020, 215:66-71. 10.1016\/j.ajo.2020.03.011","journal-title":"Am J Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfo.2014.11.015","article-title":"Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in a real-life setting","volume":"38","author":"Boulanger-Scemama E","year":"2015","unstructured":"Boulanger-Scemama E, Querques G, About F, et al.. Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in a real-life setting. J Fr Ophtalmol. 2015, 38:620-7. 10.1016\/j.jfo.2014.11.015","journal-title":"J Fr Ophtalmol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_1866_19","article-title":"Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema","volume":"68","author":"Kelkar A","year":"2020","unstructured":"Kelkar A, Webers C, Shetty R, et al.. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema. Indian J Ophthalmol. 2020, 68:2143-7. 10.4103\/ijo.IJO_1866_19","journal-title":"Indian J Ophthalmol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001494","article-title":"Natural course of patients discontinuing treatment for age-related macular degeneration and factors associated with visual prognosis","volume":"37","author":"Kim JH","year":"2017","unstructured":"Kim JH, Chang YS, Kim JW. Natural course of patients discontinuing treatment for age-related macular degeneration and factors associated with visual prognosis. Retina. 2017, 37:2254-61. 10.1097\/IAE.0000000000001494","journal-title":"Retina"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.07.010","article-title":"Outcomes of eyes lost to follow-up with neovascular age-related macular degeneration receiving intravitreal anti-vascular endothelial growth factor","volume":"4","author":"Soares RR","year":"2020","unstructured":"Soares RR, Mellen P, Garrigan H, et al.. Outcomes of eyes lost to follow-up with neovascular age-related macular degeneration receiving intravitreal anti-vascular endothelial growth factor. Ophthalmol Retina. 2020, 4:134-40. 10.1016\/j.oret.2019.07.010","journal-title":"Ophthalmol Retina"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.190","article-title":"Tailored and targeted interventions to encourage dilated fundus examinations in older African Americans","volume":"129","author":"Ellish NJ","year":"2011","unstructured":"Ellish NJ, Royak-Schaler R, Higginbotham EJ. Tailored and targeted interventions to encourage dilated fundus examinations in older African Americans. Arch Ophthalmol. 2011, 129:1592-8. 10.1001\/archophthalmol.2011.190","journal-title":"Arch Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2007.11.020","article-title":"Telephone intervention to promote diabetic retinopathy screening among the urban poor","volume":"34","author":"Walker EA","year":"2008","unstructured":"Walker EA, Schechter CB, Caban A, Basch CE. Telephone intervention to promote diabetic retinopathy screening among the urban poor. Am J Prev Med. 2008, 34:185-91. 10.1016\/j.amepre.2007.11.020","journal-title":"Am J Prev Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2105\/ajph.89.12.1878","article-title":"The effect of health education on the rate of ophthalmic examinations among African Americans with diabetes mellitus","volume":"89","author":"Basch CE","year":"1999","unstructured":"Basch CE, Walker EA, Howard CJ, Shamoon H, Zybert P. The effect of health education on the rate of ophthalmic examinations among African Americans with diabetes mellitus. Am J Public Health. 1999, 89:1878-82. 10.2105\/ajph.89.12.1878","journal-title":"Am J Public Health"},{"key":"ref28","article-title":"Personalized follow-up increases return rate at urban eye disease screening clinics for African Americans with diabetes: results of a randomized trial","volume":"13","author":"Anderson RM","year":"2003","unstructured":"Anderson RM, Musch DC, Nwankwo RB, et al.. Personalized follow-up increases return rate at urban eye disease screening clinics for African Americans with diabetes: results of a randomized trial. Ethn Dis. 2003, 13:40-6.","journal-title":"Ethn Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/164720-prevalence-and-visual-consequences-of-non-adherent-patients-receiving-anti-vascular-endothelial-growth-factor-vegf-injections-at-king-fahad-specialist-hospital-kfsh-qassim-region","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:55:47Z","timestamp":1707508547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/164720-prevalence-and-visual-consequences-of-non-adherent-patients-receiving-anti-vascular-endothelial-growth-factor-vegf-injections-at-king-fahad-specialist-hospital-kfsh-qassim-region"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.44340","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,29]]}}}